Ulrike Haug

List of Publications by Year
in descending order

96 papers	4,711 citations	117625 34 h-index	98798 67 g-index
110 all docs	110 docs citations	110 times ranked	5924 citing authors

#	Article	IF	Citations
1	Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgeryâ€"an analysis of German claims data. BMC Cancer, 2022, 22, 130.	2.6	1
2	How often are antidepressants prescribed offâ€label among older adults in Germany? A claims data analysis. British Journal of Clinical Pharmacology, 2021, 87, 1778-1789.	2.4	4
3	German Pharmacoepidemiological Research Database (GePaRD). Springer Series on Epidemiology and Public Health, 2021, , 119-124.	0.5	12
4	Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. Pharmacoepidemiology and Drug Safety, 2021, 30, 462-471.	1.9	5
5	Characteristics and Absolute Survival of Metastatic Colorectal Cancer Patients Treated With Biologics: A Real-World Data Analysis From Three European Countries. Frontiers in Oncology, 2021, 11, 630456.	2.8	7
6	Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology, 2021, 71, 101812.	1.9	3
7	Potential of German claims data to characterize utilization of new cancer drugs: the example of crizotinib. Future Oncology, 2021, 17, 2305-2313.	2.4	1
8	Characterization of pregnancies exposed to St. Johnâ€™s wort and their outcomes: A claims data analysis. Reproductive Toxicology, 2021, 102, 90-97.	2.9	2
9	Avoiding Time-Related Biases: A Feasibility Study on Antidiabetic Drugs and Pancreatic Cancer Applying the Parametric g-Formula to a Large German Healthcare Database. Clinical Epidemiology, 2021, Volume 13, 1027-1038.	3.0	3
10	Follow-up of 3 Million Persons Undergoing Colonoscopy in Germany: Utilization of Repeat Colonoscopies and Polypectomies Within 10 Years. Clinical and Translational Gastroenterology, 2021, 12, e00279.	2.5	8
11	Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis. Cancer Epidemiology, 2021, 75, 102054.	1.9	14
12	Characterization of pregnancies among women with epilepsy using valproate before or during pregnancy - A longitudinal claims data analysis. Epilepsy Research, 2021, 179, 106838.	1.6	0
13	Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine, 2020, 287, 171-179.	6.0	10
14	Linkage of Routine Data to Other Data Sources in Germany: A Practical Example Illustrating Challenges and Solutions. Gesundheitswesen, 2020, 82, S117-S121.	0.5	5
15	Promises and Potential Pitfalls of Shared Decision Making in Cancer Screening. Gastroenterology, 2020, 158, 802-805.	1.3	1
16	Estimating the Beginning of Pregnancy in German Claims Data: Development of an Algorithm With a Focus on the Expected Delivery Date. Frontiers in Public Health, 2020, 8, 350.	2.7	10
17	Different Risk Profiles of European Patients Using Direct Oral Anticoagulants or Vitamin K Antagonists: a Rapid Review. Current Epidemiology Reports, 2020, 7, 290-299.	2.4	1
18	Individual Antidepressants and the Risk of Fractures in Older Adults: A New User Active Comparator Study . Clinical Epidemiology, 2020, Volume 12, 667-678.	3.0	5

#	Article	IF	Citations
19	The cumulative false-positive rate in colorectal cancer screening: a Markov analysis. European Journal of Gastroenterology and Hepatology, 2020, 32, 575-580.	1.6	3
20	Screening des kolorektalen Karzinoms. Springer Reference Medizin, 2020, , 1-4.	0.0	0
21	Incidence of advanced colorectal cancer in Germany: comparing claims data and cancer registry data. BMC Medical Research Methodology, 2019, 19, 142.	3.1	14
22	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. BMJ: British Medical Journal, 2019, 367, l5383.	2.3	79
23	Antidepressants and the risk of traumatic brain injury in the elderly: differences between individual agents . Clinical Epidemiology, 2019, Volume 11, 185-196.	3.0	5
24	Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): a validation study using a record linkage with a large cancer registry. BMJ Open, 2019, 9, e028223.	1.9	15
25	Potential Explanations for Increasing Methylphenidate Use in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany From 2004 to 2013. Journal of Clinical Psychopharmacology, 2019, 39, 39-45.	1.4	7
26	Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: a validation study based on a record linkage with administrative mortality data. BMJ Open, 2019, 9, e026834.	1.9	10
27	Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. International Journal of Colorectal Disease, 2019, 34, 269-276.	2.2	25
28	First-degree relatives of cancer patients: a target group for primary prevention? A cross-sectional study. British Journal of Cancer, 2018, 118, 1255-1261.	6.4	13
29	Utilization of colonoscopy and colonoscopic findings among individuals aged 40â€“54 years with a positive family history of colorectal cancer: a cross-sectional study in general practice. European Journal of Cancer Prevention, 2018, 27, 539-545.	1.3	2
30	Invitation to Screening Colonoscopy in the Population at Familial Risk for Colorectal Cancer. Deutsches Ärzteblatt International, 2018, 115, 715-722.	0.9	10
31	Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety, 2018, 27, 1005-1010.	1.9	21
32	World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer. Gastroenterology, 2018, 155, 909-925.e3.	1.3	221
33	A cohort study of mammography screening finds that comorbidity measures are insufficient for controlling selection bias. Journal of Clinical Epidemiology, 2018, 104, 1-7.	5.0	4
34	Flexible sigmoidoscopy screening for colorectal cancer. BMJ: British Medical Journal, 2017, 356, j75.	2.3	2
35	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. Gut, 2017, 66, 1262-1267.	12.1	18
36	Arzneimittel in der Schwangerschaft â€“ Potenzial von SekundÃrdaten. Public Health Forum, 2017, 25, 221-223.	0.2	0

#	Article	IF	Citations
37	Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review. Journal of Global Health, 2017, 7, 020405.	2.7	11
38	Recommendations for a stepâ€wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer, 2016, 122, 826-839.	4.1	24
39	Validity of selfâ€reported family history of cancer: A systematic literature review on selected cancers. International Journal of Cancer, 2016, 139, 1449-1460.	5.1	43
40	Development of new nonâ€invasive tests for colorectal cancer screening: The relevance of information on adenoma detection. International Journal of Cancer, 2015, 136, 2864-2874.	5.1	17
41	Association between socioeconomic and demographic characteristics and utilization of colonoscopy in the EPICâ€“Heidelberg cohort. European Journal of Cancer Prevention, 2015, 24, 81-88.	1.3	8
42	Estimating Colorectal Cancer Treatment Costs: A Pragmatic Approach Exemplified by Health Insurance Data from Germany. PLoS ONE, 2014, 9, e88407.	2.5	36
43	Interval cancer: nightmare of colonoscopists: TableÂ1. Gut, 2014, 63, 865-866.	12.1	7
44	Consideration of family history of cancer in medical routine. European Journal of Cancer Prevention, 2014, 23, 199-205.	1.3	6
45	Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer Epidemiology, 2013, 37, 905-907.	1.9	21
46	Genetic Variations in the Vitamin D Binding Protein and Season-Specific Levels of Vitamin D Among Older Adults. Epidemiology, 2013, 24, 104-109.	2.7	25
47	Vitamin D Receptor Genotype rs731236 (Taq1) and Breast Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 437-442.	2.5	22
48	Serum 25-Hydroxyvitamin D and Cancer Risk in Older Adults: Results from a Large German Prospective Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 905-916.	2.5	61
49	Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. American Journal of Clinical Nutrition, 2013, 97, 782-793.	4.7	238
50	Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. British Journal of Cancer, 2012, 106, 1424-1430.	6.4	47
51	Public health implications of standardized 25-hydroxyvitamin D levels: A decrease in the prevalence of vitamin D deficiency among older women in Germany. Preventive Medicine, 2012, 55, 228-232.	3.4	27
52	A novel multiplex-protein array for serum diagnostics of colon cancer: a caseâ€“control study. BMC Cancer, 2012, 12, 393.	2.6	34
53	Subsite-specific colorectal cancer risk in the colorectal endoscopy era. Gastrointestinal Endoscopy, 2012, 75, 621-630.e1.	1.0	39
54	786 Effectiveness and Cost-Effectiveness of Once-Only Screening for Colorectal Cancer With Colonoscopy or Computed Tomographic Colonography. Gastroenterology, 2012, 142, S-141-S-142.	1.3	0

#	Article	IF	Citations
55	Standardization of Misleading Immunoassay Based 25-Hydroxyvitamin D Levels with Liquid Chromatography Tandem-Mass Spectrometry in a Large Cohort Study. PLoS ONE, 2012, 7, e48774.	2.5	46
56	How should individuals with a falseâ€positive fecal occult blood test for colorectal cancer be managed? A decision analysis. International Journal of Cancer, 2012, 131, 2094-2102.	5.1	7
57	Glutathione peroxidase tagSNPs: Associations with rectal cancer but not with colon cancer. Genes Chromosomes and Cancer, 2012, 51, 598-605.	2.8	19
58	Colorectal cancer mortality prevented by use and attributable to nonuse of colonoscopy. Gastrointestinal Endoscopy, 2011, 73, 435-443.e5.	1.0	38
59	Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. British Journal of Cancer, 2011, 104, 1779-1785.	6.4	108
60	Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecologic Oncology, 2011, 121, 369-375.	1.4	78
61	Meta-analysis: Serum vitamin D and colorectal adenoma risk. Preventive Medicine, 2011, 53, 10-16.	3.4	55
62	Authors' reply to: Acceptance quality checks for qualitative fecal immunochemical tests ensure screening program consistency. International Journal of Cancer, 2011, 128, 248-249.	5.1	0
63	Toward Standardized High-Throughput Serum Diagnostics: Multiplexâ€"Protein Array Identifies IL-8 and VEGF as Serum Markers for Colon Cancer. Journal of Biomolecular Screening, 2011, 16, 1018-1026.	2.6	44
64	Performance of Immunochemical Fecal Occult Blood Tests Among Users of Low-Dose Aspirinâ€"Reply. JAMA - Journal of the American Medical Association, 2011, 305, 1093.	7.4	0
65	Sensitivity Estimates of Blood-Based Tests for Colorectal Cancer Detection: Impact of Overrepresentation of Advanced Stage Disease. American Journal of Gastroenterology, 2011, 106, 242-253.	0.4	28
66	Is fecal occult blood testing more sensitive for left- versus right-sided colorectal neoplasia? A systematic literature review. Expert Review of Molecular Diagnostics, 2011, 11, 605-616.	3.1	37
67	Low-Dose Aspirin Use and Performance of Immunochemical Fecal Occult Blood Tests. JAMA - Journal of the American Medical Association, 2010, 304, 2513.	7.4	119
68	Interâ€test agreement and quantitative crossâ€validation of immunochromatographical fecal occult blood tests. International Journal of Cancer, 2010, 127, 1643-1649.	5.1	38
69	Response: Re: Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. Journal of the National Cancer Institute, 2010, 102, 990-991.	6.3	1
70	Sex Differences in Performance of Fecal Occult Blood Testing. American Journal of Gastroenterology, 2010, 105, 2457-2464.	0.4	115
71	Protection From Right- and Left-Sided Colorectal Neoplasms After Colonoscopy: Population-Based Study. Journal of the National Cancer Institute, 2010, 102, 89-95.	6.3	546
72	Colonoscopy Use in a Country with a Long-Standing Colorectal Cancer Screening Programme: Evidence from a Large German Survey. Zeitschrift Fur Gastroenterologie, 2010, 48, 1351-1357.	0.5	10

#	Article	IF	Citations
73	Male Sex and Smoking Have a Larger Impact on the Prevalence of Colorectal Neoplasia Than Family History of Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2010, 8, 870-876.	4.4	79
74	Population-based prevalence estimates of history of colonoscopy or sigmoidoscopy: review and analysis of recent trends. Gastrointestinal Endoscopy, 2010, 71, 366-381.e2.	1.0	53
75	Low Risk of Colorectal Cancer and Advanced Adenomas More Than 10 Years After Negative Colonoscopy. Gastroenterology, 2010, 138, 870-876.	1.3	132
76	Quantitative Immunochemical Fecal Occult Blood Testing for Colorectal Adenoma Detection: Evaluation in the Target Population of Screening and Comparison With Qualitative Tests. American Journal of Gastroenterology, 2010, 105, 682-690.	0.4	83
77	Meta-analysis: Serum vitamin D and breast cancer risk. European Journal of Cancer, 2010, 46, 2196-2205.	2.8	182
78	Metaâ€analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary Pharmacology and Therapeutics, 2009, 30, 113-125.	3.7	179
79	Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiology, 2009, 33, 435-445.	1.9	87
80	Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: Estimates based on 1,875,708 screening colonoscopies. European Journal of Cancer, 2009, 45, 2027-2033.	2.8	60
81	Comparative Evaluation of Immunochemical Fecal Occult Blood Tests for Colorectal Adenoma Detection. Annals of Internal Medicine, 2009, 150, 162.	3.9	295
82	Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. British Journal of Cancer, 2008, 99, 133-135.	6.4	54
83	Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. British Journal of Cancer, 2008, 99, 532-535.	6.4	21
84	Reply: Faecal tumour pyruvate kinase M2: not a good marker for detection of colorectal adenomas. British Journal of Cancer, 2008, 99, 1367-1367.	6.4	2
85	Evaluation of Serum and Urinary Myeloid Related Protein-14 as a Marker for Early Detection of Prostate Cancer. Journal of Urology, 2008, 180, 1309-1313.	0.4	24
86	Family History and Age at Initiation of Colorectal Cancer Screening. American Journal of Gastroenterology, 2008, 103, 2326-2331.	0.4	35
87	Stool testing for the early detection of pancreatic cancer: rationale and current evidence. Expert Review of Molecular Diagnostics, 2008, 8, 753-759.	3.1	32
88	Gender differences in colorectal cancer: implications for age at initiation of screening. British Journal of Cancer, 2007, 96, 828-831.	6.4	195
89	Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. British Journal of Cancer, 2007, 96, 1329-1334.	6.4	49
90	Mutant-Enriched PCR and Allele-Specific Hybridization Reaction to Detect K-ras Mutations in Stool DNA: High Prevalence in a Large Sample of Older Adults. Clinical Chemistry, 2007, 53, 787-790.	3.2	29

#	Article	IF	Citations
91	Risk of progression of advanced adenomas to colorectal cancer by age and sex: estimates based on 840 149 screening colonoscopies. Gut, 2007, 56, 1585-1589.	12.1	338
92	Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1935-1953.	2.5	189
93	Reply: New faecal tests for colorectal cancer screening: is tumour pyruvate kinase M2 one of the options?. British Journal of Cancer, 2007, 97, 1597-1597.	6.4	1
94	Tumor M2 Pyruvate Kinase as a Stool Marker for Colorectal Cancer: Stability at Room Temperature and Implications for Application in the Screening Setting. Clinical Chemistry, 2006, 52, 782-784.	3.2	13
95	New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness. International Journal of Cancer, 2005, 117, 169-176.	5.1	33
96	A Simulation Model for Colorectal Cancer Screening: Potential of Stool Tests with Various Performance Characteristics Compared with Screening Colonoscopy. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 422-428.	2.5	21